Targacept , Inc.  

(Public, NASDAQ:TRGT)   Watch this stock  
Find more results for TRGT
2.76
-0.01 (-0.36%)
Aug 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.72 - 2.79
52 week 2.68 - 6.11
Open 2.79
Vol / Avg. 0.00/274,261.00
Mkt cap 93.27M
P/E     -
Div/yield     -
EPS -1.47
Shares 33.79M
Beta 2.08
Inst. own 77%
Nov 3, 2014
Q3 2014 Targacept Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Aug 6, 2014
Q2 2014 Targacept, Inc. Earnings Release
Aug 6, 2014
Q2 2014 Targacept Inc Earnings Call - Webcast
Jun 5, 2014
Targacept, Inc. Annual Shareholder Meeting
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -22600.00% -1286.99%
Operating margin -22886.11% -1301.08%
EBITD margin - -1286.00%
Return on average assets -25.24% -27.85%
Return on average equity -27.07% -30.08%
Employees 39 -
CDP Score - -

Address

Suite 1510, 100 North Main Street
WINSTON-SALEM, NC 27101
United States - Map
+1-336-4802100 (Phone)
+1-336-4802107 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Targacept, Inc. is a biopharmaceutical company. The Company is engaged in the design, discovery and development of NNR Therapeutics for the treatment of diseases and disorders of the nervous system. The Company's NNR Therapeutics target neuronal nicotinic receptors (NNRs). As of December 31, 2011, the Company had multiple clinical-stage product candidates and preclinical programs in areas. The Company's drug discovery activities utilize computer-based molecular design methodologies and biological and chemical data for a library of diverse compounds developed and collected. The Company refers to these technologies collectively as Pentad. Its clinical-stage product candidates include TC-5214, TC-5619, TC-6987, AZD3480 (TC-1734), AZD1446 (TC-6683), TC-6499 and TC-6987.

Officers and directors

Stephen Anthony Hill M.D. President, Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Alan A. Musso CPA Chief Financial Officer, Senior Vice President - Finance and Administration, Treasurer, Assistant Secretary
Age: 52
Bio & Compensation  - Reuters
Patrick C. Rock J.D. Senior Vice President, General Counsel, Secretary
Age: 54
Bio & Compensation  - Reuters
David A. Hosford M.D., Ph.D., Vice President - Clinical Development and Regulatory Affairs
Age: 58
Bio & Compensation  - Reuters
Steven M. Toler Ph.D Vice President - Clinical Pharmaceutical Sciences
Age: 53
Bio & Compensation  - Reuters
John P. Richard Non-Executive Independent Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
Charles A. Blixt Esq. Independent Director
Age: 63
Bio & Compensation  - Reuters
Julia R. Brown Independent Director
Age: 66
Bio & Compensation  - Reuters
Errol B. De Souza Ph.D. Independent Director
Age: 60
Bio & Compensation  - Reuters
Alan W. Dunton M.D. Independent Director
Age: 60
Bio & Compensation  - Reuters